0

Close
 
Upcoming Allied Market Research
2023
Rapid Covid-19 Antigen Test Kit Market

Rapid Covid-19 Antigen Test Kit Market

by Product (RT-PCR Assay Kits, Immunoassay Test Strips, Cassettes), by Specimen Type (Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab), by Technology (Chromatographic Immunoassay, Fluorescent Immunoassay, Others) and by End User (Hospitals, Diagnostic Laboratories, Clinics, Homecare, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Diagnostics and Biotech
Report Code: A13377
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Rapid Covid-19 Antigen Test Kit Market

Request Now !

COVID-19 has proved to be a menace for human society for the past couple of years. It has left industries wailing, people on the back foot, and supply chain distortions. People suffering from SARS virus experience respiratory and gastrointestinal symptoms, which gradually spreads across systems in the body, thus making it essential to diagnose the virus at an early stage for effective treatment to be administered. Diagnosis is carried through rapid antigen test kit. An antigen is a molecule capable of stimulating immune response. An antigen may be proteins, nucleic acids, and polysaccharides. The antigen test predicts presence of SARS-CoV2 virus. It establishes a differentiation between body proteins and certain protein that are considered foreign to immune system. The procedure involves inserting pick inside nose and collecting a swab and further dipping it into a solution which locates the virus and inactivates it onto the testing kit. In case the test is positive, colored lines show up on the strip. Rapid antigen test kit garners certain advantages such as it reduces the burden on replying completely on RT-PCR test to identify COVID patients. In additionally, it is way cheaper than RT-PCR.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

At the early phase of the COVID-19 pandemic, there was no availability of specific diagnostic tests to detect the disease in patients. Alternative diagnostic tests were used initially but were not much effective. This unavailability of specific COVID-19 diagnostic tests presented lucrative opportunities for diagnostic manufacturers to introduce their COVID-19 diagnostic kits. Many leading players as well as some start-ups from various countries utilized this opportunity and introduced COVID-19 diagnostics kits into local as well as global markets. These players achieved an edge over other diagnostics players capitalizing on the opportunity from demand for COVID-19 diagnostic tests, which, in turn, helps them in maintaining their revenues in such a crisis.

Owing to such factors, COVID 19 is expected to have a significant impact on the rapid covid-19 antigen test Kit market.

Top Impacting Factors

  • Rising incidents in the cases of COVID-19 and the subsequent demand in rise of diagnostic tests to establish presence of SARS-CoV2 virus in anticipated to drive market growth for rapid antigen test kits.
  • Complete shift of healthcare infrastructure towards battling COVID effects coupled with rising awareness of diagnostic procedures in badly hit nations like India and Brazil is anticipated to further increase growth of rapid antigen tests. These nations are witnessing higher administrations of the test among its populace owing to daily new cases of the patients.
  • Robust government policies coupled with private sector investments into design and development of advanced diagnostic tests that can successfully detect and aid COVID treatment mechanisms is slated to increase penetration of these testing kits. Recently, in India, government announced a 10% GDP for healthcare sector in order to develop diagnostic kits.
  • Furthermore, several advantages that rapid antigen tests possess over normal RT-PCR may further boost market growth. These include high accuracy, low cost, stability, negligible side effects, etc.
  • However, prevalent misconceptions on the efficacy and reliability of the testing kits may hamper the market growth. The trend is especially more worrisome in regions with less internet connectivity and literacy levels such as Central Africa, Latin America, and North Korea.

Key Market Trends

  • North America is anticipated to continue dominance in the market owing to rising numbers of COVID-19 cases coupled with robust investments being influx into research and development of diagnostic kits.
  • Asia Pacific is picking up speed with respect to antigen diagnostic tests owing to rising incidents of infective cases due to huge population base coupled with growing demand for quick, efficient and reliable diagnosis.
  • In March 2020, SARS-Cov2 molecular test was given emergency nod by Food and Drug Administration as a potent diagnostic kit. The kit is developed by Hologenic Ltd.
  • In July 2021, Abbott labs got approval for use of its Panbio COVID-19 antigen test in European market.

Key Benefits of the Report

  • This study presents the analytical depiction of the rapid covid-19 antigen test Kit industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the rapid covid-19 antigen test Kit market share.
  • The current market is quantitatively analyzed to highlight the rapid covid-19 antigen test Kit growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Rapid Covid-19 Antigen Test Kit Report

  • Which are the leading players active in the rapid covid-19 antigen test Kit market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the rapid covid-19 antigen test Kit market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is rapid covid-19 antigen test Kit?
  • What is the rapid covid-19 antigen test Kit market prediction in the future?
  • What are the current trends and predicted trends?

 Rapid Covid-19 Antigen Test Kit Market Report Highlights

Aspects Details
By Product
  • RT-PCR Assay Kits
  • Immunoassay Test Strips
  • Cassettes
By Specimen Type
  • Nasopharyngeal Swab
  • Oropharyngeal Swab
  • Nasal Swab
By Technology
  • Chromatographic Immunoassay
  • Fluorescent Immunoassay
  • Others
By End User
  • Hospitals
  • Diagnostic Laboratories
  • Clinics
  • Homecare
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Roche, Healgen Scientific Limited, Zhejiang Orient Gene Biotech Co., Ltd., Siemens Healthineers, LumiraDX UK Ltd., Abbott, Cipla, nal von minden GmbH, Hangzhou Clongene Biotech, BIOSYNEX SWISS SA, CerTest Biotect S.L., AMEDA Labordiagnostik GmbH, Beijing Lepu Medical Technology, Becton Dickinson, Xiamen Boson Biotech Co., Quidel Corporation, SD BIOSENSOR, Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: RAPID COVID-19 ANTIGEN TEST KIT MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. RT-PCR Assay Kits

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Immunoassay Test Strips

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Cassettes

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: RAPID COVID-19 ANTIGEN TEST KIT MARKET, BY SPECIMEN TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Specimen Type

    • 5.2. Nasopharyngeal Swab

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Oropharyngeal Swab

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Nasal Swab

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: RAPID COVID-19 ANTIGEN TEST KIT MARKET, BY TECHNOLOGY

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Technology

    • 6.2. Chromatographic Immunoassay

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Fluorescent Immunoassay

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: RAPID COVID-19 ANTIGEN TEST KIT MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Hospitals

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Diagnostic Laboratories

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Clinics

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

    • 7.5. Homecare

      • 7.5.1. Key Market Trends, Growth Factors and Opportunities

      • 7.5.2. Market Size and Forecast, By Region

      • 7.5.3. Market Share Analysis, By Country

    • 7.6. Others

      • 7.6.1. Key Market Trends, Growth Factors and Opportunities

      • 7.6.2. Market Size and Forecast, By Region

      • 7.6.3. Market Share Analysis, By Country

  • CHAPTER 8: RAPID COVID-19 ANTIGEN TEST KIT MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Product

      • 8.2.3. Market Size and Forecast, By Specimen Type

      • 8.2.4. Market Size and Forecast, By Technology

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Rapid Covid-19 Antigen Test Kit Market

        • 8.2.7.1. Market Size and Forecast, By Product
        • 8.2.7.2. Market Size and Forecast, By Specimen Type
        • 8.2.7.3. Market Size and Forecast, By Technology
        • 8.2.7.4. Market Size and Forecast, By End User

      • 8.2.8. Canada Rapid Covid-19 Antigen Test Kit Market

        • 8.2.8.1. Market Size and Forecast, By Product
        • 8.2.8.2. Market Size and Forecast, By Specimen Type
        • 8.2.8.3. Market Size and Forecast, By Technology
        • 8.2.8.4. Market Size and Forecast, By End User

      • 8.2.9. Mexico Rapid Covid-19 Antigen Test Kit Market

        • 8.2.9.1. Market Size and Forecast, By Product
        • 8.2.9.2. Market Size and Forecast, By Specimen Type
        • 8.2.9.3. Market Size and Forecast, By Technology
        • 8.2.9.4. Market Size and Forecast, By End User

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Product

      • 8.3.3. Market Size and Forecast, By Specimen Type

      • 8.3.4. Market Size and Forecast, By Technology

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Rapid Covid-19 Antigen Test Kit Market

        • 8.3.7.1. Market Size and Forecast, By Product
        • 8.3.7.2. Market Size and Forecast, By Specimen Type
        • 8.3.7.3. Market Size and Forecast, By Technology
        • 8.3.7.4. Market Size and Forecast, By End User

      • 8.3.8. Germany Rapid Covid-19 Antigen Test Kit Market

        • 8.3.8.1. Market Size and Forecast, By Product
        • 8.3.8.2. Market Size and Forecast, By Specimen Type
        • 8.3.8.3. Market Size and Forecast, By Technology
        • 8.3.8.4. Market Size and Forecast, By End User

      • 8.3.9. Italy Rapid Covid-19 Antigen Test Kit Market

        • 8.3.9.1. Market Size and Forecast, By Product
        • 8.3.9.2. Market Size and Forecast, By Specimen Type
        • 8.3.9.3. Market Size and Forecast, By Technology
        • 8.3.9.4. Market Size and Forecast, By End User

      • 8.3.10. Spain Rapid Covid-19 Antigen Test Kit Market

        • 8.3.10.1. Market Size and Forecast, By Product
        • 8.3.10.2. Market Size and Forecast, By Specimen Type
        • 8.3.10.3. Market Size and Forecast, By Technology
        • 8.3.10.4. Market Size and Forecast, By End User

      • 8.3.11. UK Rapid Covid-19 Antigen Test Kit Market

        • 8.3.11.1. Market Size and Forecast, By Product
        • 8.3.11.2. Market Size and Forecast, By Specimen Type
        • 8.3.11.3. Market Size and Forecast, By Technology
        • 8.3.11.4. Market Size and Forecast, By End User

      • 8.3.12. Russia Rapid Covid-19 Antigen Test Kit Market

        • 8.3.12.1. Market Size and Forecast, By Product
        • 8.3.12.2. Market Size and Forecast, By Specimen Type
        • 8.3.12.3. Market Size and Forecast, By Technology
        • 8.3.12.4. Market Size and Forecast, By End User

      • 8.3.13. Rest Of Europe Rapid Covid-19 Antigen Test Kit Market

        • 8.3.13.1. Market Size and Forecast, By Product
        • 8.3.13.2. Market Size and Forecast, By Specimen Type
        • 8.3.13.3. Market Size and Forecast, By Technology
        • 8.3.13.4. Market Size and Forecast, By End User

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Product

      • 8.4.3. Market Size and Forecast, By Specimen Type

      • 8.4.4. Market Size and Forecast, By Technology

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Rapid Covid-19 Antigen Test Kit Market

        • 8.4.7.1. Market Size and Forecast, By Product
        • 8.4.7.2. Market Size and Forecast, By Specimen Type
        • 8.4.7.3. Market Size and Forecast, By Technology
        • 8.4.7.4. Market Size and Forecast, By End User

      • 8.4.8. Japan Rapid Covid-19 Antigen Test Kit Market

        • 8.4.8.1. Market Size and Forecast, By Product
        • 8.4.8.2. Market Size and Forecast, By Specimen Type
        • 8.4.8.3. Market Size and Forecast, By Technology
        • 8.4.8.4. Market Size and Forecast, By End User

      • 8.4.9. India Rapid Covid-19 Antigen Test Kit Market

        • 8.4.9.1. Market Size and Forecast, By Product
        • 8.4.9.2. Market Size and Forecast, By Specimen Type
        • 8.4.9.3. Market Size and Forecast, By Technology
        • 8.4.9.4. Market Size and Forecast, By End User

      • 8.4.10. South Korea Rapid Covid-19 Antigen Test Kit Market

        • 8.4.10.1. Market Size and Forecast, By Product
        • 8.4.10.2. Market Size and Forecast, By Specimen Type
        • 8.4.10.3. Market Size and Forecast, By Technology
        • 8.4.10.4. Market Size and Forecast, By End User

      • 8.4.11. Australia Rapid Covid-19 Antigen Test Kit Market

        • 8.4.11.1. Market Size and Forecast, By Product
        • 8.4.11.2. Market Size and Forecast, By Specimen Type
        • 8.4.11.3. Market Size and Forecast, By Technology
        • 8.4.11.4. Market Size and Forecast, By End User

      • 8.4.12. Thailand Rapid Covid-19 Antigen Test Kit Market

        • 8.4.12.1. Market Size and Forecast, By Product
        • 8.4.12.2. Market Size and Forecast, By Specimen Type
        • 8.4.12.3. Market Size and Forecast, By Technology
        • 8.4.12.4. Market Size and Forecast, By End User

      • 8.4.13. Malaysia Rapid Covid-19 Antigen Test Kit Market

        • 8.4.13.1. Market Size and Forecast, By Product
        • 8.4.13.2. Market Size and Forecast, By Specimen Type
        • 8.4.13.3. Market Size and Forecast, By Technology
        • 8.4.13.4. Market Size and Forecast, By End User

      • 8.4.14. Indonesia Rapid Covid-19 Antigen Test Kit Market

        • 8.4.14.1. Market Size and Forecast, By Product
        • 8.4.14.2. Market Size and Forecast, By Specimen Type
        • 8.4.14.3. Market Size and Forecast, By Technology
        • 8.4.14.4. Market Size and Forecast, By End User

      • 8.4.15. Rest of Asia Pacific Rapid Covid-19 Antigen Test Kit Market

        • 8.4.15.1. Market Size and Forecast, By Product
        • 8.4.15.2. Market Size and Forecast, By Specimen Type
        • 8.4.15.3. Market Size and Forecast, By Technology
        • 8.4.15.4. Market Size and Forecast, By End User

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Product

      • 8.5.3. Market Size and Forecast, By Specimen Type

      • 8.5.4. Market Size and Forecast, By Technology

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Rapid Covid-19 Antigen Test Kit Market

        • 8.5.7.1. Market Size and Forecast, By Product
        • 8.5.7.2. Market Size and Forecast, By Specimen Type
        • 8.5.7.3. Market Size and Forecast, By Technology
        • 8.5.7.4. Market Size and Forecast, By End User

      • 8.5.8. South Africa Rapid Covid-19 Antigen Test Kit Market

        • 8.5.8.1. Market Size and Forecast, By Product
        • 8.5.8.2. Market Size and Forecast, By Specimen Type
        • 8.5.8.3. Market Size and Forecast, By Technology
        • 8.5.8.4. Market Size and Forecast, By End User

      • 8.5.9. Saudi Arabia Rapid Covid-19 Antigen Test Kit Market

        • 8.5.9.1. Market Size and Forecast, By Product
        • 8.5.9.2. Market Size and Forecast, By Specimen Type
        • 8.5.9.3. Market Size and Forecast, By Technology
        • 8.5.9.4. Market Size and Forecast, By End User

      • 8.5.10. UAE Rapid Covid-19 Antigen Test Kit Market

        • 8.5.10.1. Market Size and Forecast, By Product
        • 8.5.10.2. Market Size and Forecast, By Specimen Type
        • 8.5.10.3. Market Size and Forecast, By Technology
        • 8.5.10.4. Market Size and Forecast, By End User

      • 8.5.11. Argentina Rapid Covid-19 Antigen Test Kit Market

        • 8.5.11.1. Market Size and Forecast, By Product
        • 8.5.11.2. Market Size and Forecast, By Specimen Type
        • 8.5.11.3. Market Size and Forecast, By Technology
        • 8.5.11.4. Market Size and Forecast, By End User

      • 8.5.12. Rest of LAMEA Rapid Covid-19 Antigen Test Kit Market

        • 8.5.12.1. Market Size and Forecast, By Product
        • 8.5.12.2. Market Size and Forecast, By Specimen Type
        • 8.5.12.3. Market Size and Forecast, By Technology
        • 8.5.12.4. Market Size and Forecast, By End User

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Abbott

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Cipla

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. AMEDA Labordiagnostik GmbH

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Becton Dickinson

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Beijing Lepu Medical Technology

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. BIOSYNEX SWISS SA

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. CerTest Biotect S.L.

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Hangzhou Clongene Biotech

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Healgen Scientific Limited

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. LumiraDX UK Ltd.

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

    • 10.11. Nal Von Minden GmbH

      • 10.11.1. Company Overview

      • 10.11.2. Key Executives

      • 10.11.3. Company Snapshot

      • 10.11.4. Operating Business Segments

      • 10.11.5. Product Portfolio

      • 10.11.6. Business Performance

      • 10.11.7. Key Strategic Moves and Developments

    • 10.12. Quidel Corporation

      • 10.12.1. Company Overview

      • 10.12.2. Key Executives

      • 10.12.3. Company Snapshot

      • 10.12.4. Operating Business Segments

      • 10.12.5. Product Portfolio

      • 10.12.6. Business Performance

      • 10.12.7. Key Strategic Moves and Developments

    • 10.13. SD BIOSENSOR, Inc.

      • 10.13.1. Company Overview

      • 10.13.2. Key Executives

      • 10.13.3. Company Snapshot

      • 10.13.4. Operating Business Segments

      • 10.13.5. Product Portfolio

      • 10.13.6. Business Performance

      • 10.13.7. Key Strategic Moves and Developments

    • 10.14. Roche

      • 10.14.1. Company Overview

      • 10.14.2. Key Executives

      • 10.14.3. Company Snapshot

      • 10.14.4. Operating Business Segments

      • 10.14.5. Product Portfolio

      • 10.14.6. Business Performance

      • 10.14.7. Key Strategic Moves and Developments

    • 10.15. Siemens Healthineers

      • 10.15.1. Company Overview

      • 10.15.2. Key Executives

      • 10.15.3. Company Snapshot

      • 10.15.4. Operating Business Segments

      • 10.15.5. Product Portfolio

      • 10.15.6. Business Performance

      • 10.15.7. Key Strategic Moves and Developments

    • 10.16. Xiamen Boson Biotech Co.

      • 10.16.1. Company Overview

      • 10.16.2. Key Executives

      • 10.16.3. Company Snapshot

      • 10.16.4. Operating Business Segments

      • 10.16.5. Product Portfolio

      • 10.16.6. Business Performance

      • 10.16.7. Key Strategic Moves and Developments

    • 10.17. Zhejiang Orient Gene Biotech Co., Ltd.

      • 10.17.1. Company Overview

      • 10.17.2. Key Executives

      • 10.17.3. Company Snapshot

      • 10.17.4. Operating Business Segments

      • 10.17.5. Product Portfolio

      • 10.17.6. Business Performance

      • 10.17.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR RT-PCR ASSAY KITS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR IMMUNOASSAY TEST STRIPS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR CASSETTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR NASOPHARYNGEAL SWAB, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR OROPHARYNGEAL SWAB, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR NASAL SWAB, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR CHROMATOGRAPHIC IMMUNOASSAY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR FLUORESCENT IMMUNOASSAY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR HOMECARE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA RAPID COVID-19 ANTIGEN TEST KIT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. U.S. RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 26. U.S. RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 27. U.S. RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 28. U.S. RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. CANADA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 30. CANADA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 31. CANADA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 32. CANADA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE RAPID COVID-19 ANTIGEN TEST KIT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 48. GERMANY RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 49. GERMANY RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. ITALY RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 51. ITALY RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 52. ITALY RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 53. ITALY RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 55. SPAIN RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. UK RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. UK RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 60. UK RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 61. UK RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. RUSSIA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 63. RUSSIA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 64. RUSSIA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 65. RUSSIA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. REST OF EUROPE RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 67. REST OF EUROPE RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 68. REST OF EUROPE RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 69. REST OF EUROPE RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC RAPID COVID-19 ANTIGEN TEST KIT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 71. ASIA-PACIFIC RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 72. ASIA-PACIFIC RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 73. ASIA-PACIFIC RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 74. ASIA-PACIFIC RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 75. CHINA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 76. CHINA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 77. CHINA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 78. CHINA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. JAPAN RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 80. JAPAN RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 81. JAPAN RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 82. JAPAN RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. INDIA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 84. INDIA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 85. INDIA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 86. INDIA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH KOREA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 91. AUSTRALIA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 92. AUSTRALIA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 93. AUSTRALIA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 94. AUSTRALIA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 95. THAILAND RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 96. THAILAND RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 97. THAILAND RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 98. THAILAND RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. MALAYSIA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 100. MALAYSIA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 101. MALAYSIA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 102. MALAYSIA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. INDONESIA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 104. INDONESIA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 105. INDONESIA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 106. INDONESIA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 107. REST OF ASIA PACIFIC RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 108. REST OF ASIA PACIFIC RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. LAMEA RAPID COVID-19 ANTIGEN TEST KIT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 112. LAMEA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 113. LAMEA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 114. LAMEA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 115. LAMEA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 116. BRAZIL RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 117. BRAZIL RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 118. BRAZIL RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 119. BRAZIL RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 120. SOUTH AFRICA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 121. SOUTH AFRICA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 122. SOUTH AFRICA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 123. SOUTH AFRICA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 124. SAUDI ARABIA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 125. SAUDI ARABIA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 126. SAUDI ARABIA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 127. SAUDI ARABIA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 128. UAE RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 129. UAE RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 130. UAE RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 131. UAE RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 132. ARGENTINA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 133. ARGENTINA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 134. ARGENTINA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 135. ARGENTINA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 136. REST OF LAMEA RAPID COVID-19 ANTIGEN TEST KIT, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 137. REST OF LAMEA RAPID COVID-19 ANTIGEN TEST KIT, BY SPECIMEN TYPE, 2022-2032 ($MILLION)
  • TABLE 138. REST OF LAMEA RAPID COVID-19 ANTIGEN TEST KIT, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 139. REST OF LAMEA RAPID COVID-19 ANTIGEN TEST KIT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 140. ABBOTT: KEY EXECUTIVES
  • TABLE 141. ABBOTT: COMPANY SNAPSHOT
  • TABLE 142. ABBOTT: OPERATING SEGMENTS
  • TABLE 143. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 144. ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. CIPLA: KEY EXECUTIVES
  • TABLE 146. CIPLA: COMPANY SNAPSHOT
  • TABLE 147. CIPLA: OPERATING SEGMENTS
  • TABLE 148. CIPLA: PRODUCT PORTFOLIO
  • TABLE 149. CIPLA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. AMEDA LABORDIAGNOSTIK GMBH: KEY EXECUTIVES
  • TABLE 151. AMEDA LABORDIAGNOSTIK GMBH: COMPANY SNAPSHOT
  • TABLE 152. AMEDA LABORDIAGNOSTIK GMBH: OPERATING SEGMENTS
  • TABLE 153. AMEDA LABORDIAGNOSTIK GMBH: PRODUCT PORTFOLIO
  • TABLE 154. AMEDA LABORDIAGNOSTIK GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 155. BECTON DICKINSON: KEY EXECUTIVES
  • TABLE 156. BECTON DICKINSON: COMPANY SNAPSHOT
  • TABLE 157. BECTON DICKINSON: OPERATING SEGMENTS
  • TABLE 158. BECTON DICKINSON: PRODUCT PORTFOLIO
  • TABLE 159. BECTON DICKINSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 160. BEIJING LEPU MEDICAL TECHNOLOGY: KEY EXECUTIVES
  • TABLE 161. BEIJING LEPU MEDICAL TECHNOLOGY: COMPANY SNAPSHOT
  • TABLE 162. BEIJING LEPU MEDICAL TECHNOLOGY: OPERATING SEGMENTS
  • TABLE 163. BEIJING LEPU MEDICAL TECHNOLOGY: PRODUCT PORTFOLIO
  • TABLE 164. BEIJING LEPU MEDICAL TECHNOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 165. BIOSYNEX SWISS SA: KEY EXECUTIVES
  • TABLE 166. BIOSYNEX SWISS SA: COMPANY SNAPSHOT
  • TABLE 167. BIOSYNEX SWISS SA: OPERATING SEGMENTS
  • TABLE 168. BIOSYNEX SWISS SA: PRODUCT PORTFOLIO
  • TABLE 169. BIOSYNEX SWISS SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 170. CERTEST BIOTECT S.L.: KEY EXECUTIVES
  • TABLE 171. CERTEST BIOTECT S.L.: COMPANY SNAPSHOT
  • TABLE 172. CERTEST BIOTECT S.L.: OPERATING SEGMENTS
  • TABLE 173. CERTEST BIOTECT S.L.: PRODUCT PORTFOLIO
  • TABLE 174. CERTEST BIOTECT S.L.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 175. HANGZHOU CLONGENE BIOTECH: KEY EXECUTIVES
  • TABLE 176. HANGZHOU CLONGENE BIOTECH: COMPANY SNAPSHOT
  • TABLE 177. HANGZHOU CLONGENE BIOTECH: OPERATING SEGMENTS
  • TABLE 178. HANGZHOU CLONGENE BIOTECH: PRODUCT PORTFOLIO
  • TABLE 179. HANGZHOU CLONGENE BIOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 180. HEALGEN SCIENTIFIC LIMITED: KEY EXECUTIVES
  • TABLE 181. HEALGEN SCIENTIFIC LIMITED: COMPANY SNAPSHOT
  • TABLE 182. HEALGEN SCIENTIFIC LIMITED: OPERATING SEGMENTS
  • TABLE 183. HEALGEN SCIENTIFIC LIMITED: PRODUCT PORTFOLIO
  • TABLE 184. HEALGEN SCIENTIFIC LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 185. LUMIRADX UK LTD.: KEY EXECUTIVES
  • TABLE 186. LUMIRADX UK LTD.: COMPANY SNAPSHOT
  • TABLE 187. LUMIRADX UK LTD.: OPERATING SEGMENTS
  • TABLE 188. LUMIRADX UK LTD.: PRODUCT PORTFOLIO
  • TABLE 189. LUMIRADX UK LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 190. NAL VON MINDEN GMBH: KEY EXECUTIVES
  • TABLE 191. NAL VON MINDEN GMBH: COMPANY SNAPSHOT
  • TABLE 192. NAL VON MINDEN GMBH: OPERATING SEGMENTS
  • TABLE 193. NAL VON MINDEN GMBH: PRODUCT PORTFOLIO
  • TABLE 194. NAL VON MINDEN GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 195. QUIDEL CORPORATION: KEY EXECUTIVES
  • TABLE 196. QUIDEL CORPORATION: COMPANY SNAPSHOT
  • TABLE 197. QUIDEL CORPORATION: OPERATING SEGMENTS
  • TABLE 198. QUIDEL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 199. QUIDEL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 200. SD BIOSENSOR, INC.: KEY EXECUTIVES
  • TABLE 201. SD BIOSENSOR, INC.: COMPANY SNAPSHOT
  • TABLE 202. SD BIOSENSOR, INC.: OPERATING SEGMENTS
  • TABLE 203. SD BIOSENSOR, INC.: PRODUCT PORTFOLIO
  • TABLE 204. SD BIOSENSOR, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 205. ROCHE: KEY EXECUTIVES
  • TABLE 206. ROCHE: COMPANY SNAPSHOT
  • TABLE 207. ROCHE: OPERATING SEGMENTS
  • TABLE 208. ROCHE: PRODUCT PORTFOLIO
  • TABLE 209. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 210. SIEMENS HEALTHINEERS: KEY EXECUTIVES
  • TABLE 211. SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
  • TABLE 212. SIEMENS HEALTHINEERS: OPERATING SEGMENTS
  • TABLE 213. SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
  • TABLE 214. SIEMENS HEALTHINEERS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 215. XIAMEN BOSON BIOTECH CO.: KEY EXECUTIVES
  • TABLE 216. XIAMEN BOSON BIOTECH CO.: COMPANY SNAPSHOT
  • TABLE 217. XIAMEN BOSON BIOTECH CO.: OPERATING SEGMENTS
  • TABLE 218. XIAMEN BOSON BIOTECH CO.: PRODUCT PORTFOLIO
  • TABLE 219. XIAMEN BOSON BIOTECH CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 220. ZHEJIANG ORIENT GENE BIOTECH CO., LTD.: KEY EXECUTIVES
  • TABLE 221. ZHEJIANG ORIENT GENE BIOTECH CO., LTD.: COMPANY SNAPSHOT
  • TABLE 222. ZHEJIANG ORIENT GENE BIOTECH CO., LTD.: OPERATING SEGMENTS
  • TABLE 223. ZHEJIANG ORIENT GENE BIOTECH CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 224. ZHEJIANG ORIENT GENE BIOTECH CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL RAPID COVID-19 ANTIGEN TEST KIT MARKET
  • FIGURE 3. SEGMENTATION RAPID COVID-19 ANTIGEN TEST KIT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN RAPID COVID-19 ANTIGEN TEST KIT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALRAPID COVID-19 ANTIGEN TEST KIT MARKET
  • FIGURE 11. RAPID COVID-19 ANTIGEN TEST KIT MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR RT-PCR ASSAY KITS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR IMMUNOASSAY TEST STRIPS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR CASSETTES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. RAPID COVID-19 ANTIGEN TEST KIT MARKET SEGMENTATION, BY BY SPECIMEN TYPE
  • FIGURE 16. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR NASOPHARYNGEAL SWAB, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR OROPHARYNGEAL SWAB, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR NASAL SWAB, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. RAPID COVID-19 ANTIGEN TEST KIT MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 20. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR CHROMATOGRAPHIC IMMUNOASSAY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR FLUORESCENT IMMUNOASSAY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. RAPID COVID-19 ANTIGEN TEST KIT MARKET SEGMENTATION, BY BY END USER
  • FIGURE 24. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR HOMECARE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. RAPID COVID-19 ANTIGEN TEST KIT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 33. COMPETITIVE DASHBOARD
  • FIGURE 34. COMPETITIVE HEATMAP: RAPID COVID-19 ANTIGEN TEST KIT MARKET
  • FIGURE 35. Top player positioning, 2022
  • FIGURE 36. ABBOTT: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. ABBOTT: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. ABBOTT: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. CIPLA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. CIPLA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. CIPLA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. AMEDA LABORDIAGNOSTIK GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. AMEDA LABORDIAGNOSTIK GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. AMEDA LABORDIAGNOSTIK GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. BECTON DICKINSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. BECTON DICKINSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. BECTON DICKINSON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. BEIJING LEPU MEDICAL TECHNOLOGY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. BEIJING LEPU MEDICAL TECHNOLOGY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. BEIJING LEPU MEDICAL TECHNOLOGY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. BIOSYNEX SWISS SA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. BIOSYNEX SWISS SA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. BIOSYNEX SWISS SA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. CERTEST BIOTECT S.L.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. CERTEST BIOTECT S.L.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. CERTEST BIOTECT S.L.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. HANGZHOU CLONGENE BIOTECH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. HANGZHOU CLONGENE BIOTECH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. HANGZHOU CLONGENE BIOTECH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. HEALGEN SCIENTIFIC LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. HEALGEN SCIENTIFIC LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. HEALGEN SCIENTIFIC LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. LUMIRADX UK LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. LUMIRADX UK LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. LUMIRADX UK LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 66. NAL VON MINDEN GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. NAL VON MINDEN GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 68. NAL VON MINDEN GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 69. QUIDEL CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. QUIDEL CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 71. QUIDEL CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 72. SD BIOSENSOR, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 73. SD BIOSENSOR, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 74. SD BIOSENSOR, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 75. ROCHE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 76. ROCHE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 77. ROCHE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 78. SIEMENS HEALTHINEERS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 79. SIEMENS HEALTHINEERS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 80. SIEMENS HEALTHINEERS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 81. XIAMEN BOSON BIOTECH CO.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 82. XIAMEN BOSON BIOTECH CO.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 83. XIAMEN BOSON BIOTECH CO.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 84. ZHEJIANG ORIENT GENE BIOTECH CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 85. ZHEJIANG ORIENT GENE BIOTECH CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 86. ZHEJIANG ORIENT GENE BIOTECH CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Rapid Covid-19 Antigen Test Kit Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers